Damora Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Damora Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($209.84M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($21.44M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($38.35M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($61.62M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($51.75M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($34.84M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($36.51M) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.87M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($22.26M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($39.91M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($61.21M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($52.23M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($33.64M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $38.97M | Mar 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.88M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.40M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $23.77M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $48.21M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $38.49M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $24.63M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $19.74M | Mar 29, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.73M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($18.62M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($36.91M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($42.93M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($52.31M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($38.20M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($19.33M) | Mar 29, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $196.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $223.0K | Mar 9, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.53M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $17.13M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $38.23M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $73.19M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $122.22M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $171.60M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $56.61M | Mar 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.15M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.30M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $5.90M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $11.44M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $4.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.11M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $8.14M | Mar 29, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.38M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.83M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $32.33M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $61.75M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | $117.22M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $165.49M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | ($71.15M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($33.84M) | Mar 29, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($487.36M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($277.52M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($256.09M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($217.74M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($156.11M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($104.36M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($69.52M) | Mar 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.62M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $14.18M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $21.47M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $32.79M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $62.56M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $163.58M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $11.29M | Mar 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (18) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (36) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (18) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (36) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.60M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 1.32M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 1.08M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 25.65M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 25.26M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 25.26M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 259,966 | Mar 29, 2021 |